Q1 Earnings Estimate for EBS Issued By Benchmark

Emergent Biosolutions Inc. (NYSE:EBS) – Equities research analysts at Benchmark issued their Q1 2026 earnings per share estimates for Emergent Biosolutions in a research report issued to clients and investors on Tuesday, April 21st. Benchmark analyst R. Wasserman expects that the biopharmaceutical company will post earnings of ($0.25) per share for the quarter.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54). The firm had revenue of $148.70 million during the quarter, compared to analysts’ expectations of $217.50 million. Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%.

EBS has been the subject of a number of other research reports. HC Wainwright lowered their price target on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 9th. Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 2nd. Finally, Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Stock Up 3.6%

Shares of NYSE EBS opened at $8.28 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. The firm has a market capitalization of $427.79 million, a price-to-earnings ratio of 9.86 and a beta of 2.35. The stock has a 50 day moving average price of $8.86 and a 200 day moving average price of $10.36. Emergent Biosolutions has a 52-week low of $4.71 and a 52-week high of $14.06.

Hedge Funds Weigh In On Emergent Biosolutions

A number of large investors have recently bought and sold shares of EBS. Millennium Management LLC raised its stake in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after buying an additional 1,020,582 shares in the last quarter. Jain Global LLC bought a new position in Emergent Biosolutions in the third quarter worth approximately $4,487,000. HRT Financial LP bought a new position in Emergent Biosolutions in the fourth quarter worth approximately $3,853,000. Dimensional Fund Advisors LP raised its stake in Emergent Biosolutions by 15.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,140,340 shares of the biopharmaceutical company’s stock worth $18,878,000 after buying an additional 291,308 shares in the last quarter. Finally, Jump Financial LLC raised its stake in Emergent Biosolutions by 468.4% in the third quarter. Jump Financial LLC now owns 314,000 shares of the biopharmaceutical company’s stock worth $2,769,000 after buying an additional 258,757 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.